Autres langues PharmaEngine, Inc.

Actions

4162

TW0004162003

Cours en clôture Taipei Exchange Autres places de cotation 00:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
91,5 ^TWD	+0,99 %		+2,81 %	-13,27 %

24/04	PharmaEngine, Inc. annonce le premier patient traité dans le cadre de l'essai de phase I du PEP07 pour les tumeurs solides	CI
18/03	PharmaEngine, Inc. annonce que l'ONIVYDE obtient l'approbation de la TFDA pour un nouveau régime dans le traitement de première ligne du PDAC métastatique	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors	24/04
PharmaEngine, Inc. Announces ONIVYDE Obtains TFDA Approval for New Regimen in First-Line Treatment of Metastatic PDAC	18/03
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
PharmaEngine, Inc. Announces Consolidated Revenue Results for the Month and Year Ended December 2023	29/02
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/11
TFDA Approves PharmaEngine, Inc.'s PEP07 Phase I Clinical Trial for Solid Tumor Cancers	22/09/23
PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of Pep07 for Hematological Cancers	15/08/23
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	05/08/23
PharmaEngine, Inc. Announces Dividend, Payable on September 1, 2023	27/07/23
PharmaEngine, Inc. Announces EMAs Acceptance of Onivyde's Type II Variation Application	11/07/23
PharmaEngine, Inc. Files Post-Approval Change Application for A New Indication of ONIVYDE to TFDA	21/06/23
PharmaEngine, Inc. Announces Approval of Phase 1 Clinical Study of Pep07 by TFDA	14/06/23
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23
PharmaEngine, Inc. Announces Resignation of Peter Wu as Senior Director of Marketing & Sales	27/04/23
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/03/23
Australia HREC Approves and Australia TGA Acknowledges PharmaEngine, Inc.'s Phase 1 Clinical Study of PEP07	03/03/23
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	04/11/22
PharmaEngine, Inc. Announces Change of Board of Directors Chairperson	01/09/22
PharmaEngine, Inc. Announces Management Changes, Effective September 1, 2022	30/08/22
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/08/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues PharmaEngine, Inc.

Actions

4162

TW0004162003

Autres langues

Filtres